The LixiRam study, sponsored by Sanofi, evaluates the safety and efficacy of Lixisenatide compared to Sulfonylurea in patients with Type 2 Diabetes Mellitus who intend to fast during Ramadan. This trial is particularly relevant given the growing prevalence of diabetes in the Middle East and South Asia, where fasting during Ramadan is common. The results could position Lixisenatide favorably against traditional therapies, potentially increasing its market share in the diabetes treatment landscape. The trial's completion and subsequent data could enhance Sanofi's competitive edge, especially in regions with significant Muslim populations. Additionally, the focus on safety during fasting may attract attention from healthcare providers and patients alike, emphasizing the importance of tailored diabetes management strategies.